Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + medroxyprogesterone acetate
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intramuscular
01
Overview
This is a combination drug consisting of fluorouracil (5-FU), an antimetabolite chemotherapeutic agent, and medroxyprogesterone acetate (MPA), a synthetic progestin hormone. Fluorouracil acts primarily by inhibiting thymidylate synthase, thereby interfering with DNA synthesis and inducing cell death in rapidly dividing cancer cells. Medroxyprogesterone acetate exerts its effects as a progestogen, modulating hormone-responsive tumors by altering the hormonal environment and directly affecting tumor growth. The combination has been studied for enhanced antitumor efficacy in certain cancers, particularly metastatic or recurrent endometrial carcinoma, where it may provide additive or synergistic effects compared to monotherapy[1][4][9]. This regimen is not widely marketed under a unique brand name but has been investigated in clinical settings.
- Other names
- 5-fluorouracil + medroxyprogesterone acetate
02
Targets
TS (Thymidylate synthase)PR (Progesterone receptor)
Beyond the preview
Go deeper on fluorouracil + medroxyprogesterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + medroxyprogesterone acetate.